(Q74561988)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9591806%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

review article

1 reference

title

Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9591806%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

E A Mullans

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9591806%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

P R Cohen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9591806%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

language of work or name

English

0 references

publication date

1 May 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9591806%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American Academy of Dermatology

11 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9591806%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9591806%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

5 Pt 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9591806%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

866-873

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9591806%20AND%20SRC:MED&resulttype=core&format=json

A cutaneous syndrome associated with islet-cell carcinoma of the pancreas

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

A glucagonoma syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Histologic variation in the skin lesions of the glucagonoma syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic Migratory Erythema Without Glucagonoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic migratory erythema-like dermatitis with malabsorption

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Glucagonoma syndrome and bronchial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic migratory erythema with elevated plasma enteroglucagon in celiac disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic migratory erythema: association with neuroendocrine tumour with predominant insulin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic migratory erythema without glucagonoma: the role of dietary essential fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic migratory erythema without glucagonoma versus canine superficial necrolytic dermatitis: Is hepatic impairment a clue to pathogenesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic migratory erythema without glucagonoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

[Isolated zinc deficiency and necrolytic migratory erythema. Apropos of a case]

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic migratory erythema without glucagonoma in a heroin-dependent patient

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic migratory erythema: a report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

[Erythema necroticans migrans without glucagonoma]

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic migratory erythema without glucagonoma in patients with liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Hyperglucagonaemia and associated skin lesions following traumatic necrotizing pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

[Pseudoglucagonoma syndrome. Case report, therapeutic possibilities and hypotheses on the etiology]

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic acral erythema: a cutaneous marker of viral hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic migratory erythema without glucagonoma in patients with liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Hypoglycemia Associated with Non-Islet-Cell Tumor and Insulin-like Growth Factors

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Role of Insulin-Like Growth Factor II and IGF Binding Proteins in Extrapancreatic Tumor Hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Disappearance of glucagonoma rash after surgical resection, but not during dietary normalization of serum amino acids

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Glucagonoma syndrome: In vitro evidence that glucagon increases epidermal arachidonic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

A dermatosis specifically associated with a tumour of pancreatic alpha cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Necrolytic migratory erythema. Distinctive dermatosis of the glucagonoma syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

The glucagonoma syndrome: Surgically curable diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Glucagonoma syndrome. A clinicopathologic, immunocytochemical, and ultrastructural study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Rapid improvement of skin lesions in glucagonomas with intravenous somatostatin infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Effect of somatostatin in necrolytic migratory erythema of glucagonoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Successful treatment of glucagonoma-related necrolytic migratory erythema with dacarbazine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Hepatic tumors with hyperglucagonemia. Response to treatment with human lymphoblastoid interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Presence of glucagon immunoreactivity in the globulin fraction of human plasma ("big plasma glucagon").

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Plasma immunoreactive glucagon fractions in four cases of glucagonoma: Increased “Large glucagon — immunoreactivity”

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Glucagon levels and metabolic effects in fasting man

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Treatment of necrolytic migratory erythema in glucagonoma syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Amino Acid Deficiency and the Skin Rash Associated with Glucagonoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

A familial glucagonoma syndrome: genetic, clinical and biochemical features

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Glucagonoma Syndrome: Case Report and Literature Review

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Nutritional deficiency and the skin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

Essential Fatty Acid Deficiency in Human Adults During Total Parenteral Nutrition

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970478-5

7 January 2021

10.1016/S0190-9622(98)70478-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9591806%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference